AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.085|
|52 Week High||AU$0.08|
|52 Week Low||AU$0.27|
|1 Month Change||-13.27%|
|3 Month Change||-3.41%|
|1 Year Change||-26.09%|
|3 Year Change||-69.64%|
|5 Year Change||-55.26%|
|Change since IPO||-69.64%|
Recent News & Updates
We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, AdAlta ( ASX:1AD...
|1AD||AU Biotechs||AU Market|
Return vs Industry: 1AD underperformed the Australian Biotechs industry which returned 2.5% over the past year.
Return vs Market: 1AD underperformed the Australian Market which returned 21.3% over the past year.
Stable Share Price: 1AD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 1AD's weekly volatility (8%) has been stable over the past year.
About the Company
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company’s lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd.
AdAlta Fundamentals Summary
|1AD fundamental statistics|
Is 1AD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1AD income statement (TTM)|
|Cost of Revenue||AU$201.22k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.023|
|Net Profit Margin||-141.26%|
How did 1AD perform over the long term?See historical performance and comparison
Is AdAlta undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 1AD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 1AD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 1AD is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: 1AD is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1AD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1AD is good value based on its PB Ratio (3.3x) compared to the AU Biotechs industry average (5x).
How is AdAlta forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1AD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1AD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1AD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1AD's revenue is expected to decline over the next 3 years (-11.4% per year).
High Growth Revenue: 1AD's revenue is forecast to decline over the next 3 years (-11.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1AD's Return on Equity is forecast to be high in 3 years time
How has AdAlta performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1AD is currently unprofitable.
Growing Profit Margin: 1AD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 1AD is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare 1AD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1AD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48%).
Return on Equity
High ROE: 1AD has a negative Return on Equity (-88.13%), as it is currently unprofitable.
How is AdAlta's financial position?
Financial Position Analysis
Short Term Liabilities: 1AD's short term assets (A$9.0M) exceed its short term liabilities (A$2.7M).
Long Term Liabilities: 1AD has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 1AD's debt to equity ratio (26.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 1AD's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1AD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 1AD has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 17.6% each year.
What is AdAlta current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1AD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1AD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1AD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1AD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1AD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Timothy Charles Oldham, also known as Tim, B.Sc (Hons), L.L.B. (Hons), Ph D., has been Chief Executive Officer, Managing Director and Director of AdAlta Limited since October 8, 2019. Prior to this, he...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD374.33K) is about average for companies of similar size in the Australian market ($USD302.38K).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
Experienced Management: 1AD's management team is considered experienced (4 years average tenure).
Experienced Board: 1AD's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AdAlta Limited's employee growth, exchange listings and data sources
- Name: AdAlta Limited
- Ticker: 1AD
- Exchange: ASX
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$20.840m
- Shares outstanding: 245.18m
- Website: https://www.adalta.com.au
- AdAlta Limited
- 2 Park Drive
- Unit 15
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 16:53|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.